



Agenda Item No: 3.4

Business Board Co-opted Memberships

To:	Business Board
Meeting Date:	16 March 2021
Public report:	Yes
Lead Member:	Chair of the Business Board, Austen Adams
From:	Business Programmes and Business Board Manager, Domenico Cirillo
Key decision:	No
Recommendation:	<p>The Business Board is recommended to:</p> <p>Appoint Mike Herd and Dr Andy Williams as non-voting co-opted members of the Business Board.</p>

1. Purpose

- 1.1 To appoint both Mike Herd of The Alpha Group and Dr Andy Williams of Astra Zeneca as non-voting co-opted members on the Business Board.

2. Background

- 2.1 The CPCA Assurance Framework (November 2019 - p20, para 3.3.38) states that where specific skills or abilities are required which are not available among existing members, the Board may appoint up to five co-opted members as necessary to complement the skills and expertise on the Business Board. Co-opted members are proposed due to the skills and abilities that can be brought to the Business Board, by these individuals which are outlined in 2.4 below.
- 2.2 The Chair of the Business Board supports these appointments. The appointments will be made for an initial term of 12 months.
- 2.3 Co-opted members will not have voting rights and will not count towards decision-making quoracy.

2.4 Co-opted members do not count towards the LEP Board membership gender or protected characteristic diversity and private sector representation requirements.

2.4 Details of the proposed candidates to be co-opted onto the Business Board are as follows:

- Mike Herd – an experienced innovation and business growth coach, facilitator and advisor for entrepreneurs, supporting businesses overcome challenges and to realise their potential. As the Regional Director for The Alpha Group, Mike is committed to developing effective strategies for better professional and business performance.
- Dr Andy Williams - since the arrival of AstraZeneca's strategic R&D Centre and global head office in Cambridge, Andy has been working closely with regional and national stakeholders to develop the local infrastructure and promoting the life sciences sector through extensive local community outreach activities. Andy has been an active contributor to evolving Cambridge's thinking in areas like transport, skill development, community amenity, housing and digital enablement.

2.5 All new members of the Business Board are required to undertake a full induction. The proposed co-opted members would be invited to attend the next Business Board meeting on 12 May 2021.

3. Financial Implications

3.1 At its meeting on 31 July 2019 the Cambridgeshire and Peterborough Combined Authority, having regard to a report prepared by the East Cambridgeshire District Council's Independent Remuneration Panel, approved the adoption of a Members Allowance Scheme to remunerate private sector members of the Business Board, with effect from 24 September 2018.

3.2 As private sector members, and as set out within the adopted Members Allowance Scheme, both co-optees would receive an annual allowance of £5,000.

3.3 Additional funding of £10k p.a. is required to support these appointments as they increase the number of board members. All Board allowances are funded 25% from the Business Board Allowances budget line (funded from Enterprise Zone Receipts) and 75% from the Local Growth Fund (LGF) Costs budget line (funded from the LGF Top-Slice), and both approved budgets have the headroom to facilitate this increase for 2021-22 and 2022-23. The Top-Slice will be fully spent at the end of March 2023 and an alternative funding source will be sought prior to this.

4. Legal Implications

4.1 None

5. Other Significant Implications

5.1 None

6. Appendices

6.1 None

7. Background Papers

7.1 CPCA Assurance Framework – [Assurance Framework \(November 2019\)](#)

7.2 'Business Board Allowances' – [Agenda Item No. 1.7 \(CA Board Meeting – 31st July 2019\)](#)

7.3 Members Allowances Scheme – [Members Allowances Scheme for the Business Board](#)